High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria

International Journal of Antimicrobial Agents

Volumn 35, Issue 4, 2010, Pages 400-404

  Shen, Gwan Han ^a,b,c   Wu, Bo Da ^a   Hu, Shiau Ting ^d   Lin, Chen Fu ^a   Wu, Kun Ming ^e   Chen, Jiann Hwa ^f  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e Rui Fu Shi Medical Laboratory   (Taiwan)

^f NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Amikacin; Clofazimine; Mycobacterium abscessus; Mycobacterium chelonae; Mycobacterium fortuitum

Indexed keywords

AMIKACIN; CLOFAZIMINE; CYCLOSERINE; DAPSONE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BROTH DILUTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; PRIORITY JOURNAL;

AMIKACIN; ANTI-BACTERIAL AGENTS; CLOFAZIMINE; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS, ATYPICAL;

EID: 76749105098     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.008     Document Type: Article

References (15)

1. Shen G.H., Wu B.D., Wu K.M., and Chen J.H. In vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 51 (2007) 1849-1851
2. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 (2007) 367-416 [Erratum. Am J Respir Crit Care Med 2007;175:744-5]
3. Abate G., Miorner H., Ahmed O., and Hoffner S.E. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis 2 (1998) 580-584
4. Franzblau S.G. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system. Antimicrob Agents Chemother 33 (1989) 2115-2117
5. Rastogi N., Goh K.S., and Labrousse V. Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms. Eur J Clin Microbiol Infect Dis 12 (1993) 954-958
6. da Silva Telles M.A., Chimara E., Ferrazoli L., and Riley L.W. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 54 (2005) 975-979
7. Ausina V., Condom M.J., Mirelis B., Luquin M., Coll P., and Prats G. In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Antimicrob Agents Chemother 29 (1986) 951-952
8. Gomez-Flores R., Gupta S., Tamez-Guerra R., and Mehta R.T. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J Clin Microbiol 33 (1995) 1842-1846
9. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardiae, and other Aerobic Actinomycetes; Approved Standard. Document M24-A (2003), NCCLS, Wayne, PA
10. De Logu A., Onnis V., Saddi B., Congiu C., Schivo M.L., and Cocco M.T. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 49 (2002) 275-282
11. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52 (2003) 1
12. Reddy V.M., O'Sullivan J.F., and Gangadharam P.R. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 43 (1999) 615-623
13. Ballarino G.J., Olivier K.N., Claypool R.J., Holland S.M., and Prevots D.R. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 103 (2009) 1448-1455
14. Bulatovic V.M., Wengenack N.L., Uhl J.R., Hall L., Roberts G.D., Cockerill III F.R., et al. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 46 (2002) 2765-2771
15. Fattorini L., Li B., Piersimoni C., Tortoli E., Xiao Y., Santoro C., et al. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrob Agents Chemother 39 (1995) 680-685